#3982
Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study
Introduction:
After the approval of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Japan (June 2021), its treatment experience is increasing, but limited data are available in Japanese patients with neuroendocrine neoplasm (NEN).
Conference:
Presenting Author:
Authors:
Okamoto K,
Hijioka S,
Goto Y,
Honma Y,
Hirano H,
Keywords:
PRRT,
177Lu-DOTATATE,
Japanese cohort,
#3040
Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction:
Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Jann H
Authors:
Feldhaus F,
Jann H,
Jonczyk M,
Boening G,
Wieners G,
Keywords:
brachytherapy,
afterloading,
hepatic metastases,
local tumor ablation,
local tumor control,
#2121
Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy
Introduction:
Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Ichikawa Y,
Kobayashi N,
Tokuhisa M,
Goto A,
Hiroshima Y,
Keywords:
Neuroendocrine Carcinoma,
Temozolomide,
